EGFR and head and neck squamous cell carcinoma: In conclusion, though the degree of benefit from a single treatment timepoint greatly varies among different cell lines, reducing PIK3C2A mRNA levels sensitized HNSCC cell lines to EGFR inhibition with gefitinib.